Type 2 Diabetes Melitus

Metabolic Diseases
1
Pipeline Programs
1
Companies
25
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

On Market (1)

Approved therapies currently available

Takeda
OSENIApproved
alogliptin benzoate and pioglitazone hydrochloride
Takeda
oral2013

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
OSENI(Alogliptin)N/ASmall Molecule5 trials
Active Trials
NCT03042325Withdrawn0Est. Jan 2018
NCT03555565Completed1,026Est. Oct 2019
NCT02856113Completed152Est. Feb 2022
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin
TakedaAlogliptin

Showing 15 of 25 trials with date data

Clinical Trials (25)

Total enrollment: 41,284 patients across 25 trials

NCT03042325TakedaAlogliptin

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

Start: Jul 2017Est. completion: Jan 20180
Phase 4Withdrawn
NCT02856113TakedaAlogliptin

Phase 3 Alogliptin Pediatric Study

Start: Oct 2016Est. completion: Feb 2022152 patients
Phase 3Completed
NCT02068443TakedaAlogliptin

Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

Start: Feb 2014Est. completion: Feb 2015374 patients
Phase 3Completed
NCT01632007TakedaAlogliptin

Double-blind Comparative Study of SYR-472

Start: May 2012Est. completion: Jul 2013245 patients
Phase 3Completed
NCT01456130TakedaAlogliptin

Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes

Start: Nov 2011Est. completion: Mar 201367 patients
Phase 3Completed
NCT01023581TakedaAlogliptin

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

Start: Nov 2009Est. completion: Jun 2011784 patients
Phase 3Completed
NCT00968708TakedaAlogliptin

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

Start: Sep 2009Est. completion: Jun 20135,380 patients
Phase 3Completed
NCT00856284TakedaAlogliptin

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Start: Mar 2009Est. completion: Oct 20122,639 patients
Phase 3Completed
NCT00707993TakedaAlogliptin

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

Start: Jun 2008Est. completion: Aug 2010441 patients
Phase 3Completed
NCT00286468TakedaAlogliptin

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

Start: Apr 2006Est. completion: Jun 2007500 patients
Phase 3Completed
NCT00286455TakedaAlogliptin

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

Start: Feb 2006Est. completion: Jul 2007329 patients
Phase 3Completed
NCT00286429TakedaAlogliptin

Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

Start: Feb 2006Est. completion: May 2007390 patients
Phase 3Completed
NCT01318135TakedaAlogliptin

Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

Start: Jan 2009Est. completion: Apr 2010576 patients
Phase 2/3Completed
NCT01318083TakedaAlogliptin

Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

Start: Aug 2008Est. completion: Apr 2009312 patients
Phase 2/3Completed
NCT01318109TakedaAlogliptin

Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan

Start: Aug 2008Est. completion: Apr 2009288 patients
Phase 2/3Completed
NCT02508168TakedaAlogliptin

Phase 1 Bioavailability Study of SYR-322MET

Start: Apr 2016Est. completion: Apr 201624 patients
Phase 1Completed
NCT01391663TakedaAlogliptin

Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

Start: Jul 2011Est. completion: Sep 201148 patients
Phase 1Completed
NCT00957268TakedaAlogliptin

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

Start: Sep 2009Est. completion: Nov 201346 patients
Phase 1Completed
NCT03555565TakedaAlogliptin

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Start: Feb 2017Est. completion: Oct 20191,026 patients
N/ACompleted
NCT02756832TakedaAlogliptin

An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2

Start: Sep 2016Est. completion: Apr 20181,409 patients
N/ACompleted
NCT02221284TakedaAlogliptin

Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"

Start: Jun 2014Est. completion: Jun 2017964 patients
N/ACompleted
NCT04980040TakedaAlogliptin

A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

Start: Apr 2014Est. completion: Aug 20193,623 patients
N/ACompleted
NCT01964963TakedaAlogliptin

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Start: Aug 2011Est. completion: Jul 201719,192 patients
N/ACompleted
NCT01964950TakedaAlogliptin

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea

Start: Jul 2011Est. completion: Dec 20141,101 patients
N/ACompleted
NCT01945242TakedaAlogliptin

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"

Start: Mar 2011Est. completion: Jun 20141,374 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Manager, Patient Safety and Pharmacovigilance Operations

Kailera Therapeutics
Waltham, Massachusetts
9h ago

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
Yesterday

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Application & Integration Architect

Roche
Indianapolis
5d ago
$106K - $196K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)